Talquetamab Continuous To Demonstrate High Overall Response Rates in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - April 1, 2025 599 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MonumenTAL-1 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Aumolertinib FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration MOST POPULAR A Propensity Score Matched Study Supports the Use of Allogeneic HSCT... May 12, 2023 FDA Grants Accelerated Approval to Zanubrutinib for Relapsed or Refractory Follicular... March 22, 2024 Reflecting on COVID-19 and the Importance of Providing Information to People... July 21, 2022 Tagraxofusp Proves Effective for BPDCN, A Rare Blood Cancer May 15, 2019 Load more HOT NEWS Significant iDFS Benefit with Adding Ribociclib to a Nonsteroidal Aromatase Inhibitor... Alex Trebek Has Completed Chemo And Will Be Back For The... Why haven’t we cured cancer? Trial Results Support SBRT as a Standard Option for Some Prostate...
